Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company focused on the life sciences and biopharmaceutical sector, targeting businesses engaged in translational medicine and drug development. The company filed a Form 10-Q with the SEC on May 15, 2026, under accession number 0001104659-26-061556, reflecting its status as an active reporting entity. TDAC falls within the broader healthcare SPAC universe, which has drawn significant sponsor attention given the sector's capital intensity and pipeline-driven valuation dynamics. For full filing history, trust account details, merger timeline, and comparable SPAC data, sign up for a SpacDesk account at spacdesk.com.